List of Selzentry drug patents

Selzentry is owned by Viiv Hlthcare.

Selzentry contains Maraviroc.

Selzentry has a total of 3 drug patents out of which 2 drug patents have expired.

Expired drug patents of Selzentry are:

  • US6667314*PED
  • US7368460

Selzentry was authorised for market use on 04 November, 2016.

Selzentry is available in solution;oral dosage forms.

Selzentry can be used as method of treating patients infected with ccr5-tropic hiv-1.

The generics of Selzentry are possible to be released after 30 April, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6667314

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
Feb, 2022

(11 months ago)

US7368460 VIIV HLTHCARE Tropane derivatives useful in therapy
Nov, 2022

(2 months ago)

US7368460

(Pediatric)

VIIV HLTHCARE Tropane derivatives useful in therapy
May, 2023

(3 months from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Oct 30, 2023
Pediatric Exclusivity (PED) Apr 30, 2024

Drugs and Companies using MARAVIROC ingredient

Market Authorisation Date: 04 November, 2016

Treatment: Method of treating patients infected with ccr5-tropic hiv-1

Dosage: SOLUTION;ORAL

How can I launch a generic of SELZENTRY before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in